Biontech Se Stock Buy Hold or Sell Recommendation
| BNTX Stock | USD 88.01 1.20 1.38% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BioNTech SE is 'Strong Hold'. Macroaxis provides BioNTech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BioNTech positions. The advice algorithm takes into account all of BioNTech's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting BioNTech's buy or sell advice are summarized below:
Real Value 104.26 | Target Price 151.1 | Hype Value 88.55 | Market Value 88.01 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell BioNTech SE given historical horizon and risk tolerance towards BioNTech. When Macroaxis issues a 'buy' or 'sell' recommendation for BioNTech SE, the advice is generated through an automated system that utilizes algorithms and statistical models.
BioNTech |
Execute BioNTech Buy or Sell Advice
The BioNTech recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioNTech SE. Macroaxis does not own or have any residual interests in BioNTech SE or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioNTech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
BioNTech Trading Alerts and Improvement Suggestions
| BioNTech SE generated a negative expected return over the last 90 days | |
| BioNTech SE has a very strong financial position based on the latest SEC filings | |
| About 63.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNTech SE Shares Sold by Vontobel Holding Ltd. - MarketBeat |
BioNTech Returns Distribution Density
The distribution of BioNTech's historical returns is an attempt to chart the uncertainty of BioNTech's future price movements. The chart of the probability distribution of BioNTech daily returns describes the distribution of returns around its average expected value. We use BioNTech SE price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioNTech returns is essential to provide solid investment advice for BioNTech.
| Mean Return | -0.17 | Value At Risk | -2.17 | Potential Upside | 2.21 | Standard Deviation | 1.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioNTech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioNTech Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioNTech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioNTech SE backward and forwards among themselves. BioNTech's institutional investor refers to the entity that pools money to purchase BioNTech's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2023-09-30 | 546.5 K | Voloridge Investment Management, Llc | 2023-09-30 | 530.5 K | Millennium Management Llc | 2023-09-30 | 498.4 K | Clearbridge Advisors, Llc | 2023-09-30 | 484.1 K | Dekabank Deutsche Girozentrale | 2023-12-31 | 425.1 K | First Trust Advisors L.p. | 2023-12-31 | 416.9 K | Gilder Gagnon Howe & Co Llc | 2023-12-31 | 359.7 K | Bamco Inc | 2023-12-31 | 242.3 K | Fmr Inc | 2023-09-30 | 237.8 K | Baillie Gifford & Co Limited. | 2023-12-31 | 8.7 M | Primecap Management Company | 2023-12-31 | 4.8 M |
BioNTech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (5.8M) | (49.8M) | (438.4M) | 62.9M | 81.9M | 86.0M | |
| Investments | (77.1M) | (144.8M) | (566.1M) | (35.3M) | (7.0B) | (6.6B) | |
| Change In Cash | 107.7M | 691.1M | 482.5M | 12.2B | (2.2B) | (2.1B) | |
| Net Borrowings | 3.5M | 7.9M | 141.7M | (66.7M) | (76.7M) | (72.9M) | |
| Free Cash Flow | (269.6M) | (98.9M) | 735.7M | 13.2B | 4.7B | 2.8B | |
| Depreciation | 33.9M | 38.7M | 75.2M | 123.3M | 183.4M | 192.6M | |
| Other Non Cash Items | 262K | 114.5M | 212.5M | (4.1B) | (1.3B) | (1.2B) | |
| Capital Expenditures | 71.1M | 85.4M | 154M | 363.3M | 705.5M | 740.8M | |
| Net Income | (179.4M) | (145.8M) | 15.0B | 13.0B | 1.2B | 1.1B | |
| End Period Cash Flow | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
| Change To Netincome | 8.2M | 30.1M | 25.7M | 1.3B | 1.4B | 1.5B |
BioNTech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioNTech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioNTech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioNTech stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.22 | |
β | Beta against NYSE Composite | 0.61 | |
σ | Overall volatility | 1.61 | |
Ir | Information ratio | -0.16 |
BioNTech Volatility Alert
BioNTech SE exhibits very low volatility with skewness of 0.4 and kurtosis of 1.84. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure BioNTech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact BioNTech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.BioNTech Fundamentals Vs Peers
Comparing BioNTech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioNTech's direct or indirect competition across all of the common fundamentals between BioNTech and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioNTech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioNTech's fundamental indicators could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioNTech to competition |
| Fundamentals | BioNTech | Peer Average |
| Return On Equity | 0.0462 | -0.31 |
| Return On Asset | 0.0262 | -0.14 |
| Profit Margin | 0.24 % | (1.27) % |
| Operating Margin | 0.40 % | (5.51) % |
| Current Valuation | 4.31 B | 16.62 B |
| Shares Outstanding | 240.99 M | 571.82 M |
| Shares Owned By Insiders | 62.84 % | 10.09 % |
| Shares Owned By Institutions | 18.33 % | 39.21 % |
| Number Of Shares Shorted | 3.08 M | 4.71 M |
| Price To Earning | 5.19 X | 28.72 X |
| Price To Book | 0.96 X | 9.51 X |
| Price To Sales | 5.46 X | 11.42 X |
| Revenue | 3.82 B | 9.43 B |
| Gross Profit | 16.07 B | 27.38 B |
| EBITDA | 1.16 B | 3.9 B |
| Net Income | 1.19 B | 570.98 M |
| Cash And Equivalents | 9.33 B | 2.7 B |
| Cash Per Share | 38.30 X | 5.01 X |
| Total Debt | 219.1 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 5.15 X | 2.16 X |
| Book Value Per Share | 85.17 X | 1.93 K |
| Cash Flow From Operations | 5.37 B | 971.22 M |
| Short Ratio | 4.33 X | 4.00 X |
| Earnings Per Share | 4.09 X | 3.12 X |
| Price To Earnings To Growth | 0.04 X | 4.89 X |
| Target Price | 118.43 | |
| Number Of Employees | 6.13 K | 18.84 K |
| Beta | 0.23 | -0.15 |
| Market Capitalization | 20.92 B | 19.03 B |
| Total Asset | 23.01 B | 29.47 B |
| Retained Earnings | 19.76 B | 9.33 B |
| Working Capital | 17.46 B | 1.48 B |
BioNTech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioNTech . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 13223.76 | |||
| Daily Balance Of Power | 0.5405 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 87.61 | |||
| Day Typical Price | 87.74 | |||
| Price Action Indicator | 1.0 | |||
| Period Momentum Indicator | 1.2 |
About BioNTech Buy or Sell Advice
When is the right time to buy or sell BioNTech SE? Buying financial instruments such as BioNTech Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 301.5M | 212.2M | 219.1M | 161.3M | Total Assets | 15.8B | 23.3B | 23.0B | 24.2B |
Use Investing Ideas to Build Portfolios
In addition to having BioNTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Growth Funds Thematic Idea Now
Small Growth Funds
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioNTech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.09 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.